GGrantIndex
Sort

10,766 grants matching “checkpoint inhibitor”

Personal tumor neoantigens for immunity against chronic lymphocytic leukemia

$771,133
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · R01 · FY2022 · CA

Building the foundations of commensal vaccines

$770,910
Michael Andrew Fischbach · Stanford University · R01 · FY2023 · AI

Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors

$770,888
Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA

Novel Telomere-Targeting Therapy for Advanced Non-Small Cell Lung Cancer

$770,168
Victor Zaporojan · Maia Biotechnology, Inc. · R44 · FY2025 · CA

Promoting Kidney Transplantation Tolerance Through Novel Immunomodulation and Cellular Therapy

$769,707
Andrew B Adams · University Of Minnesota · U19 · FY2025 · AI

Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas

$769,404
Joana M Murad · Celdara Medical, Llc · R44 · FY2023 · CA

Immune Checkpoints in Acute Respiratory Distress Syndrome (IC-ARDS)

$769,298
Carmen R Mikacenic · Benaroya Research Inst At Virginia Mason · R01 · FY2020 · HL

Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening

$768,819
Joseph C Wu · Stanford University · R01 · FY2022 · HL

Spatially resolved, single cell biomarkers of B cell lymphoma

$768,055
Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2024 · CA

Dietary regulation of anti-tumor immunity through caloric restriction

$767,324
Russell Jones · Van Andel Research Institute · U01 · FY2025 · CA

Immunotherapeutic targeting of gangliosides in Ewing Sarcoma

$767,167
Robbie G. Majzner · Dana-Farber Cancer Inst · U01 · FY2025 · CA

A Multi-Institute Survivorship Study of Patients Living with Advanced Cancer Who Have Had Durable Response to Immune Checkpoint Inhibitors

$766,294
Theresa E Hahn · Roswell Park Cancer Institute Corp · R01 · FY2025 · CA

ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas

$766,065
David M. Ashley · Duke University · R01 · FY2025 · CA

Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies

$765,000
Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2018 · CA

Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies

$765,000
Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2019 · CA

Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies

$765,000
Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2021 · CA

Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies

$765,000
Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2022 · CA

Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies

$765,000
Zachary Scott Morris · University Of Wisconsin-Madison · U01 · FY2020 · CA

Microglia-specific proteomic mechanisms and biomarkers of neuroinflammation in Alzheimer’s disease

$764,472
Srikant Rangaraju · Yale University · R01 · FY2024 · AG

Chemoenzymatic glycan editing for deciphering biological functions of glycans

$764,241
Peng Wu · Scripps Research Institute, The · R35 · FY2022 · GM

Chemoenzymatic glycan editing for deciphering biological functions of glycans

$764,241
Peng Wu · Scripps Research Institute, The · R35 · FY2023 · GM

Impact of Interventions on Clonally Expanded Proviruses and Their RNA Expression

$763,826
Mary Kearney · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA

Novel SCD1 inhibitors for treatment of cancer

$763,181
John A Copland · Modulation Therapeutics, Inc. · R42 · FY2018 · CA

Lympocyte Activation Gene-3 Deficiency Linked to Proinflammation and Atherosclerosis

$762,674
Annabelle Rodriguez · University Of Connecticut Sch Of Med/Dnt · R01 · FY2016 · HL

Identifying cellular and molecular signatures from distinct T cell receptor clonotypes associated with favorable immune checkpoint inhibitor responses in HNSCCs

$762,411
Robert L Ferris · Univ Of North Carolina Chapel Hill · R01 · FY2025 · DE